株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

ユーイング肉腫:パイプライン製品の分析

Ewing Sarcoma - Pipeline Review, H2 2016

発行 Global Markets Direct 商品コード 229774
出版日 ページ情報 英文 210 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
ユーイング肉腫:パイプライン製品の分析 Ewing Sarcoma - Pipeline Review, H2 2016
出版日: 2016年11月16日 ページ情報: 英文 210 Pages
概要

ユーイング肉腫は原発性の骨肉腫で、主に子供や青少年に多く見られます。ユーイング肉腫は子供時代や青少年期に起こりやすく、通常思春期の成長期に発症します。最も一般的な症状は、疼痛と、時折患部が腫れるということがあります。また、一見軽傷に見えた腫瘍患部の骨が折れる子供もいます。

当レポートでは、ユーイング肉腫の治療薬開発パイプラインの現況と最新アップデートによる各開発段階の比較分析、企業や研究機関によって開発中の治療薬、治療薬の評価、後期段階および中止されたプロジェクトに関する情報などを最新のニュースや発表も交えて提供しています。

イントロダクション

  • 調査範囲

ユーイング肉腫の概要

治療薬の開発

  • パイプライン製品の概要
  • パイプライン製品の比較分析

ユーイング肉腫:企業で開発中の治療薬

ユーイング肉腫:大学/機関で研究中の治療薬

ユーイング肉腫:パイプライン製品の概況

  • 臨床段階の製品
  • 初期段階の製品

ユーイング肉腫:企業で開発中の製品

ユーイング肉腫:大学/機関で研究中の製品

ユーイング肉腫の治療薬開発に従事している企業

  • アステラス製薬
  • Cebiotex, S.L.
  • Celgene Corporation
  • EntreChem, S.L.
  • Exelixis, Inc.
  • Gradalis Inc.
  • Ipsen S.A.
  • Kolltan Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Merrimack Pharmaceuticals, Inc.
  • NanoSmart Pharmaceuticals, Inc.
  • Nanovalent Pharmaceuticals Inc.
  • NantKwest, Inc.
  • Novartis AG
  • Oncomatryx Biopharma, S.L.
  • Recombio S.L
  • 塩野義製薬
  • Sigma-Tau S.p.A.
  • Tesaro, Inc.
  • Tokalas, Inc.

ユーイング肉腫:治療薬の評価

  • 単剤製品
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤プロファイル

ユーイング肉腫:最近のパイプライン動向

ユーイング肉腫:休止中のプロジェクト

ユーイング肉腫:開発が中止された製品

ユーイング肉腫:製品開発のマイルストーン

  • 主なニュースとプレスリリース

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8657IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Ewing Sarcoma - Pipeline Review, H2 2016, provides an overview of the Ewing Sarcoma (Oncology) pipeline landscape.

Ewing's sarcoma is a primary bone cancer that affects mainly children and adolescents. Ewing's sarcoma can occur any time during childhood and young adulthood, but usually develops during puberty, when bones are growing rapidly. There are few symptoms. The most common is pain and occasionally swelling at the site of the tumor. Children may also break a bone at the site of the tumor after a seemingly minor injury.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Ewing Sarcoma - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Ewing Sarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Ewing Sarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Ewing Sarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 9, 7, 14 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 3, 1 and 2 molecules, respectively.Ewing Sarcoma.

Ewing Sarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Ewing Sarcoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Ewing Sarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Ewing Sarcoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Ewing Sarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Ewing Sarcoma (Oncology)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Ewing Sarcoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Ewing Sarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Ewing Sarcoma Overview
  • Therapeutics Development
    • Pipeline Products for Ewing Sarcoma - Overview
  • Pipeline Products for Ewing Sarcoma - Comparative Analysis
  • Ewing Sarcoma - Therapeutics under Development by Companies
  • Ewing Sarcoma - Therapeutics under Investigation by Universities/Institutes
  • Ewing Sarcoma - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Ewing Sarcoma - Products under Development by Companies
  • Ewing Sarcoma - Products under Investigation by Universities/Institutes
  • Ewing Sarcoma - Companies Involved in Therapeutics Development
    • Astellas Pharma Inc.
    • Cebiotex, S.L.
    • Celgene Corporation
    • EntreChem, S.L.
    • Exelixis, Inc.
    • Gradalis Inc.
    • Kolltan Pharmaceuticals, Inc.
    • Merck & Co., Inc.
    • Merrimack Pharmaceuticals, Inc.
    • NanoSmart Pharmaceuticals, Inc.
    • Nanovalent Pharmaceuticals Inc.
    • NantKwest, Inc.
    • Novartis AG
    • Oncomatryx Biopharma, S.L.
    • Oncternal Therapeutics, Inc.
    • Pfizer Inc.
    • Pharma Mar, S.A.
    • Recombio S.L
    • Shionogi & Co., Ltd.
    • Tesaro, Inc.
  • Ewing Sarcoma - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • axitinib - Drug Profile
    • cabozantinib s-malate - Drug Profile
    • CEB-01 - Drug Profile
    • Cellular Immunotherapy for Oncology - Drug Profile
    • Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile
    • celyvir - Drug Profile
    • Drugs to Inhibit Sirtuin 1 for Ewing Sarcoma - Drug Profile
    • EC-8042 - Drug Profile
    • EC-8105 - Drug Profile
    • everolimus - Drug Profile
    • gemogenovatucel-T - Drug Profile
    • haNK Program - Drug Profile
    • irinotecan hydrochloride - Drug Profile
    • KITSG-3227 - Drug Profile
    • KTN-0182A - Drug Profile
    • linsitinib - Drug Profile
    • lurbinectedin - Drug Profile
    • Monoclonal Antibody Conjugate for Ewing Sarcoma - Drug Profile
    • Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile
    • niraparib - Drug Profile
    • NV-101 - Drug Profile
    • OMTX-503 - Drug Profile
    • OMTX-703 - Drug Profile
    • ONC-206 - Drug Profile
    • paclitaxel albumin bound - Drug Profile
    • pazopanib hydrochloride - Drug Profile
    • pembrolizumab - Drug Profile
    • racotumomab - Drug Profile
    • RNAi Gene Therapy to Inhibit EWS-FLI1 for Ewing Sarcoma - Drug Profile
    • roneparstat - Drug Profile
    • S-588410 - Drug Profile
    • Small Molecules for Ewing Sarcoma - Drug Profile
    • SP-2509 - Drug Profile
    • SP-2528 - Drug Profile
    • SP-2577 - Drug Profile
    • TK-216 - Drug Profile
    • Vimo-101 - Drug Profile
  • Ewing Sarcoma - Dormant Projects
  • Ewing Sarcoma - Discontinued Products
  • Ewing Sarcoma - Product Development Milestones
    • Featured News & Press Releases
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Ewing Sarcoma, H2 2016
  • Number of Products under Development for Ewing Sarcoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016 (Contd..1)
  • Products under Investigation by Universities/Institutes, H2 2016
  • Ewing Sarcoma - Pipeline by Astellas Pharma Inc., H2 2016
  • Ewing Sarcoma - Pipeline by Cebiotex, S.L., H2 2016
  • Ewing Sarcoma - Pipeline by Celgene Corporation, H2 2016
  • Ewing Sarcoma - Pipeline by EntreChem, S.L., H2 2016
  • Ewing Sarcoma - Pipeline by Exelixis, Inc., H2 2016
  • Ewing Sarcoma - Pipeline by Gradalis Inc., H2 2016
  • Ewing Sarcoma - Pipeline by Kolltan Pharmaceuticals, Inc., H2 2016
  • Ewing Sarcoma - Pipeline by Merck & Co., Inc., H2 2016
  • Ewing Sarcoma - Pipeline by Merrimack Pharmaceuticals, Inc., H2 2016
  • Ewing Sarcoma - Pipeline by NanoSmart Pharmaceuticals, Inc., H2 2016
  • Ewing Sarcoma - Pipeline by Nanovalent Pharmaceuticals Inc., H2 2016
  • Ewing Sarcoma - Pipeline by NantKwest, Inc., H2 2016
  • Ewing Sarcoma - Pipeline by Novartis AG, H2 2016
  • Ewing Sarcoma - Pipeline by Oncomatryx Biopharma, S.L., H2 2016
  • Ewing Sarcoma - Pipeline by Oncternal Therapeutics, Inc., H2 2016
  • Ewing Sarcoma - Pipeline by Pfizer Inc., H2 2016
  • Ewing Sarcoma - Pipeline by Pharma Mar, S.A., H2 2016
  • Ewing Sarcoma - Pipeline by Recombio S.L, H2 2016
  • Ewing Sarcoma - Pipeline by Shionogi & Co., Ltd., H2 2016
  • Ewing Sarcoma - Pipeline by Tesaro, Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Ewing Sarcoma - Dormant Projects, H2 2016
  • Ewing Sarcoma - Dormant Projects (Contd..1), H2 2016
  • Ewing Sarcoma - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Ewing Sarcoma, H2 2016
  • Number of Products under Development for Ewing Sarcoma - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top